Answers are grounded in this paper and cite their sources.
• Precise Targeted Drug Delivery • A GPC1-targeted liposomal nanoplatform was constructed taking advantage of GPC-1, which is overexpressed in PDAC, to address insufficient targeting in pancreatic cancer. Benefiting from liposomes’ biocompatibility and high encapsulation efficiency, it precisely accumulates PTX and reduces off-target toxicity. Cell experiments confirmed the platform specifically recognizes GPC1-highly expressed PDAC cells, with significantly enhanced cellular uptake versus non-targeted carriers, fully validating its in vitro targeting specificity. • Synergistic Strategy of Chemotherapy and SDT • This study innovatively combines PTX-based chemotherapy with Ce6-mediated sonodynamic therapy (SDT). Chemotherapy induces cell cycle arrest, while SDT generates reactive oxygen species (ROS), exerting dual effects to synergistically damage tumor cells and overcome drug resistance limitations of monotherapy. Apoptosis assays clearly demonstrated the synergy between PTX chemotherapy and Ce6-mediated SDT, which significantly enhanced inhibitory effects on drug-resistant PDAC cells, outperforming single therapies. • Mechanism Validation of Cavitation-Enhanced Endocytosis • Cell experiments showed SDT increased cell membrane permeability, promoted changes in membrane potential, improved nano-carrier endocytosis efficiency, and elevated intracellular drug and ROS levels. This provides robust in vitro mechanistic support for the synergistic therapeutic effect, clarifying how cavitation effects potentiate intracellular drug delivery. • In Vitro Safety and Translational Potential Validation • Cytotoxicity assays indicated the liposomal nanoplatform exhibits low toxicity to normal cells and excellent biocompatibility without ultrasonic irradiation. Under ultrasound, it exerts significant therapeutic activity in PDAC cell lines, laying a solid in vitro foundation for subsequent in vivo experiments and clinical translation, and highlighting its translational potential. Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most malignant tumours with limited treatment options and poor prognosis. This study designed a targeting nanoplatform, GCP@NBs, combining Paclitaxel (PTX)-mediated chemotherapy and Chlorin e6 (Ce6)-assisted sonodynamic therapy (SDT) for PDAC. In vitro targeting ability was validated via glypican-1 antibodies (GPC1-Abs) on the surface. Phase transition of perfluoropentane (PFP) facilitated the ultrasound (US) imaging and the controlled drug release. Live/Dead cell dual-fluorescence staining and flow cytometry were performed to corroborate cell apoptosis. Meanwhile, the generation of reactive oxygen species (ROS) was confirmed by ROS Content Detection Kit. Mitochondrial Membrane Potential (MMP) Assay kit was leveraged to verify the depolarization of MMP, and Western blot was performed to reveal the expression of proteins involved in apoptosis. Additionally, biosafety of GCP@NBs in the absence of US irradiation was validated. Consequently, GCP@NBs exhibited optimal particle size of 378.4 ± 10.54 nm and surface charge of -22.63 ± 0.32 mV, showing excellent stability and drug loading capacity (47.35 ± 0.21% for Ce6 and 64.80 ± 0.19% for PTX). GCP@NBs showed good biosafety and US imaging capability, exhibited specific targeting ability and cellular uptake, demonstrated efficient drug release and US-responsive ROS generation, and achieved excellent anti-cancer effects at low concentration. JC-1 staining showed the obvious MMP depolarization, and Western blot illustrated the increased expression of caspase-3 and Bax/Bcl-2 ratio during the cell apoptosis process. This study highlights the potential of GCP@NBs as novel and highly effective nanoplatforms for treatment of PDAC.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: